Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Dermatologic 1

Conditions

Myeloproliferative Syndrome, Transient 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9fludarabine 8Cytarabine 8Busulfan 8Azacitidine 8Whole-Body Irradiation 7Methotrexate 7Cyclosporine 6Tacrolimus 5Filgrastim 5Decitabine 5nilotinib 4Mycophenolic Acid 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Dasatinib 3Biopsy 3AP 1903 reagent 3venetoclax 2sabatolimab 2ruxolitinib 2merphos 2magrolimab 2ivosidenib 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Observation × Myeloid × Clear all
NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Children's Oncology Group

Phase 3 Withdrawn
MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡